MENU
+Compare
CARA
Stock ticker: NASDAQ
AS OF
Apr 15, 04:59 PM (EDT)
Price
$5.45
Change
-$0.10 (-1.80%)
Capitalization
25.38M

CARA stock forecast, quote, news & analysis

Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus... Show more

Industry: #Biotechnology
CARA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for CARA with price predictions
Apr 14, 2025

CARA's RSI Oscillator recovers from overbought zone

The 10-day RSI Oscillator for CARA moved out of overbought territory on March 24, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 instances where the indicator moved out of the overbought zone. In of the 24 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for CARA crossed bearishly below the 50-day moving average on April 09, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CARA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CARA broke above its upper Bollinger Band on March 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where CARA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on April 14, 2025. You may want to consider a long position or call options on CARA as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CARA just turned positive on April 14, 2025. Looking at past instances where CARA's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

CARA moved above its 50-day moving average on April 14, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CARA advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 114 cases where CARA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CARA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.113) is normal, around the industry mean (13.464). P/E Ratio (0.000) is within average values for comparable stocks, (63.084). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.770). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (3.549) is also within normal values, averaging (249.955).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CARA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.08B. The market cap for tickers in the group ranges from 31.65 to 281.29B. NONOF holds the highest valuation in this group at 281.29B. The lowest valued company is CYCCP at 31.65.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 9%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was -21%. PHIO experienced the highest price growth at 114%, while MMIRF experienced the biggest fall at -72%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -5%. For the same stocks of the Industry, the average monthly volume growth was 44% and the average quarterly volume growth was 30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 74
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
CARA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
400 Atlantic Street
Phone
+1 203 406-3700
Employees
55
Web
https://www.caratherapeutics.com